Kornimate/medical-research-clean huggingface dataset:
rapamycin as treatment for autosomal dominant polycystic kidney disease (adpkd): the role of biomarkers in predicting a response to therapy

Conditions: Autosomal Dominant Polycystic Kidney Disease

Summary: currently the only approved use for rapamycin (sirolimus) is for immunosuppression after renal transplantation. this trial is designed to determine whether rapamycin is safe and effective treatment for patients with polycystic kidney disease (adpkd). patients will be followed by volumetric magnetic resonance imaging (mri) to observe for change in kidney (and cyst) size. blood and urine samples will also be collected to evaluate for change in biomarkers with treatment.

this is a 2 year, open label trial to evaluate the role of rapamycin as treatment for adpkd. patients will be randomized 2:1 to the rapamycin arm or to standard therapy. the dose of rapamycin will be adjusted so that patients obtain 24 trough levels of 4-6ng/ml. there will be a volumetric mri measurement at the start and end of the treatment period. patients will be monitored every 4 months throughout the study.

Eligibility criteria:
inclusion criteria: * adult adpkd patients aged 18-70 * combined kidney volume \>1200 ml * estimated creatinine clearance \>60 ml/min * absence of implanted ferromagnetic objects exclusion criteria: * age \>70 * uncontrolled hyperlipidemia * proteinuria \>500 mg/day * unstable cerebral aneurysm * active coronary artery disease * diagnosis of another systemic condition affecting kidney function (ie: diabetes, hepatitis b or c, hiv) * diagnosis of cancer other than skin cancer * pregnancy or lactation * presence of implanted ferromagnetic objects

Keywords: autosomal dominant polycystic kidney disease rapamycin adpkd
assesment of post-stroke elbow flexor spasticity in different forearm positions

Conditions: Post-stroke Elbow Spasticity

Summary: determination of which muscle is more spastic before injection of the botulinum toxin, and the application of the targeted treatment to that muscle results in more improvement in spasticity. it is known that the muscles that flex elbow in healthy individuals change according to forearm position. while the biceps brachii flexes the forearm in supination, the brachioradialis flexes the forearm in the neutral position. the brachialis muscle acts as a primary flexor muscle when the forearm is in pronation. in this study, hypothesis is that the severity of spasticity differs depending on the forearm position.

there are three main muscles that contribute to elbow flexor spasticity; musculus biceps brachii, musculus brachialis and musculus brachioradialis. muscle selection in elbow flexor spasticity for botulinum toxin application has impact on treatment outcome. the superficiality of the biceps brachii muscle makes it an easy target for botulinum toxin injection. in dynamic electromyography studies, it has been reported that brachioradialis muscle is the most common contributor one to elbow flexion spasticity, followed by biceps brachii muscle. in the diagnostic selective nerve blocks, the brachialis muscle has been reported to be foreground. determination of which muscle is more spastic before injection of the botulinum toxin, and the application of the targeted treatment to that muscle results in more improvement in spasticity. can the target muscle selection clinically be performed instead of methods such as electromyography where equipment is required and the evaluation period is relatively long? can semi-quantitative methods used to assess the severity of spasticity provide reliable information regarding the muscle or muscles that contribute to elbow flexor spasticity? it is known that the muscles that flex elbow in healthy individuals change according to forearm position. while the biceps brachii flexes the forearm in supination, the brachioradialis flexes the forearm in the neutral position. the brachialis muscle acts as a primary flexor muscle when the forearm is in pronation. the aim of this study is to investigate whether the severity of spasticity differs depending on the forearm position.

Eligibility criteria:
inclusion criteria: * elbow flexor spasticity * grade 1 to 3 spasticity measured with modified ashworth scale * to agree to participate in the study exclusion criteria: * \<18 years old * pregnancy * botulinum toxin injection within the last three months * presence of elbow contracture * history of operation to spastic upper extremity * spasticity due to other causes other than stroke * do not agree to participate in the study

Keywords: elbow spasticity stroke
determination of predictive value of echography doppler abnormalities

Conditions: Breast Cancer; Upper Extremity Deep Vein Thrombosis, Secondary

Summary: in order to avoid to use a traumatic and iatrogenic examen (phlebography), the purpose of the study is to validate echography doppler in the diagnosis of asymptomatic related catheter related thrombosis.

phlebography is the gold standard for the diagnosis of asymptomatic catheter related thrombosis but can not be performed in about 15% of patients because of arm swelling and lack of superficial veins. echography doppler is an easy, cheap and atraumatic way to make the diagnosis of deep vein thrombosis. the value of echography doppler has been proven for the diagnosis of symptomatic deep venous thrombosis of lower and upper limbs and for the diagnosis of proximal asymptomatic lower limbs. to validate the echography doppler we intend to correlate asymptomatic findings to the occurrence symptomatic related catheter related thrombosis. patients with localized breast cancer treated with chemotherapy will be enrolled in the study. an echography doppler will be performed on day 8, 30 and 90 after catheter insertion. findings in asymptomatic patients (thrombus visualisation, lack of vein compressibility, variation of physiologic vein blood flow) will thereafter be correlated with the presence or absence of clinical signs of catheter related thrombosis. in order to assess if they are risk factors for catheter related thrombosis, we will determine the level d-dimer, microparticles and the results of generation thrombin tests before and 2 days after catheter insertion.

Eligibility criteria:
inclusion criteria: * women over 18 * histologically proven breast cancer * localized breast cancer without metastasis * adjuvant or neo adjuvant chemotherapy * insertion of central catheter with port for chemotherapy * central catheter for more than three months * inform consent * follow up for three months exclusion criteria: * ongoing anticoagulant therapy * previous central catheter * femoral catheter * double lumen catheter * central catheter without port * platelets \< 80g/l, tq \< 50%, fibrinogen \< 1 g/l * creatinin \> 175mole/l

Keywords: breast cancer catheter related thrombosis diagnosis echography doppler risk factors
the clinical manifestations of the severe acute respiratory syndrome, coronavirus 2( sars-cov-2 ); not only pulmonary

Conditions: Covid19

Summary: a prospective observational study to identify different extrapulmonary clinical manifestations of sars-cov-2 and its correlations with the disease severity grades.

the current research in this area was retrospective trials; this study is a prospective one. investigators will perform the extensive recording of extrapulmonary manifestations in adult patients of sars-cov-2 and their correlations with the disease severity grades. type of the study: a prospective observational study study setting: data will be collected from outpatients and inpatients files and a questionnaire. sample size calculation: depending on the average monthly (40-50 cases) and type of the study : -investigators will use steven k. thompson equation 13 to calculate the size from the next formula population size =(752) sample size = (414) level of confidence: ( 95%) error proportion: (0.05) probability :(20 %) study power: (80 %)

Eligibility criteria:
inclusion criteria: * patients have been confirmed diagnosed with covid-19 disease by pcr * patients aged 18 years and above exclusion criteria: * patients aged below 18 years old.
clinical efficacy and safety evaluation of hcp1904-1 in essential hypertension patients

Conditions: Hypertension

Summary: the purpose of this study is to evaluate of efficacy and safety of hcp1904-1 and rld2001-1 alone in patients with essential hypertension inadequately controlled on rld2001-1 monotherapy.

a multi-center, randomized, double-blinded, active-controlled, parallel, phse iii study to evaluate the efficacy and safety of hcp1904-1 in essential hypertension patients

Eligibility criteria:
inclusion criteria: 1. patients over 18 years of age 2. patients who understands the process of clinical study and voluntarily signs a peer letter 3. visit1: a person whose blood pressure measured in visit1 corresponds to the following conditions * blood pressure medication taken patients: 130mmhg ≤ sitsbp\<180mmhg, sitdbp\<110mmhg * blood pressure medication free patients: 140mmhg ≤ sitsbp\<180mmhg, sitdbp\<110mmhg 4. visit2: 140mmhg ≤ sitsbp\<180mmhg, sitdbp\<110mmhg or if patients are in high risk group: 130mmhg ≤ sitsbp \<180mmhg, sit dbp \< 110mmhg exclusion criteria: * difference in mean value of blood pressure measured in both arms of more than 20mmhg in sitsbp or more than 10mmhg in sitdbp * orthostatic hypotension with symptoms within 3months of visit 1 * secondary hypertensive patient or suspected to be * uncontrolled diabetes mellitus(hba1c \> 9%) or type i diabetes mellitus * active gout or hyperuricemia (uric acid ≥ 9mg/dl) * severe heart disease or severe neurovascular disease * severe or malignant retinopathy * clinically significant hematological finding * severe renal diseases (egfr\<30ml/min/1.73m2) * severe hepatopathy or active hepatopathy (ast or alt normal range ≥ 3 times) * hypokalemia or hyperkalemia(k\<3.5mmol/l or k ≥ 5.5mmol/l) * hyponatremia or hypernatremia(na\<135mmol/l or na ≥ 155mmol/l) * hypercalcemia * history of malignancy tumor * history of autoimmune disease * history of alcohol or drug abuse * positive to pregnancy test, nursing mother, intention on pregnancy * considered by investigator as not appropriate to participate in the clinical study with othe reason

Keywords: losartan chlorthalidone
impact of fish oil supplementation in 3rd trimester of pregnancy on maternal and offspring health

Conditions: Preterm Delivery; Atopy; Metabolic Syndrome

Summary: the aim of the trial is to investigate the effect of daily supplementation with 2.7 grams of long chain n-3 fatty acids during the third trimester of pregnancy. in 1990, 533 pregnant women, while they were in gestational week 30, were randomized to fish oil supplements providing the mentioned amount of long chain n-3 fatty acids, olive oil supplements, or no supplements; they were asked to take the supplements until delivery. health outcomes were assessed during pregnancy and delivery. further, offspring health and development has been examined during the ensuring two decades by making linkages to the rich danish health and administrative registries, by asking the offspring to complete web-based questionnaires, and by examining the offspring physically.


Eligibility criteria:
inclusion criteria: * healthy pregnant women in gestation week 30 exclusion criteria: * bleeding episodes during pregnancy

Keywords: fish oil pregnancy rct birth weight gestational age asthma and allergies metabolic syndrome obesity
comparison between home macular perimeter and optical coherence tomography (oct) visual field defects in patients with choroidal neovascularization (cnv)

Conditions: Age Related Macular Degeneration; Choroidal Neovascularization

Summary: the foresee home is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with age related macular degeneration (amd). however, the device has the ability to detect the development of the lesion post treatment and therefore to assess in determination of the next treatment. the optical coherence tomography (oct) may be used as well to identify choroidal neovascularization (cnv). comparison between the two methods will allow better understanding of both devices. the foresee home can be used as an assessment tool for the progression and success of the treatment given to amd lesions. therefore, evaluating the size and the location of the treated lesions may serve as an additional tool.


Eligibility criteria:
inclusion criteria: * for naïve cnv lesion - diagnosed in less than 60 days. or for re-activated cnv lesion - treated more than 4 month from the diagnosis. * intent to treat the study eye (se) * corrected va better than 6/45 (20/150) in se * subject is capable and willing to sign a consent form and participate in the study * age \> 55 years * subject declared that he or she knows how to operate a computer mouse exclusion criteria: * evidence of macular disease other than amd or glaucoma in se * presence of any significant media opacity that precludes a clear view of the macular area as identified in the se by biomicroscopy * any ocular surgery performed within 3 months prior to study entry in the se \* participation in another study

Keywords: cnv amd wet-treated cnv
the effective and safety of thalidomide in ntdt

Conditions: Thalassemia

Summary: this is an exploratory experiment, aims to explore the effective and safety of thalidomide in the treatment of ntdt to improve the hemoglobin level, improve the quality of life, reduce blood transfusion, so as to avoid the adverse reactions caused by transfusion.15\~30 patients will be enrolled, including type α 5\~13 cases, type β 10\~17 cases.

the project is a single arm research of thalidomide in ntdt,patients volunteered to participate in this trial and met the following inclusion criteria will be enrolled: age from 18\~65, eastern cooperative oncology group (ecog) performance status score of 2 or less. subjects should take thalidomide 50mg per day for 12 weeks. during this time, hepatic and renal function, hematologic function, electrocardiogram and the adverse reactions were closely observed. according to the protocol, the blood routine, peripheral blood reticulocyte count, nucleated red blood cell count, hemoglobin electrophoresis and other indicators were evaluated in screening-period visit, 4-weeks visit, 8-weeks visit and 12-weeks visit.

Eligibility criteria:
inclusion criteria: patients meeting all of the following criteria will be considered for admission to the trial: * diagnosis of ntdt; * ages 18-65 years; * ecog: 0\~2 scores; * sign an informed consent agreeing to the clinical trial participation. exclusion criteria: patients presenting with any of the following criteria will not be included in the trial: * patients received hydroxycarbamide, yisui shengxue granule in three months; * women during pregnancy, breastfeeding or those of childbearing age who do not want to take contraceptive measures; * patients had comorbidities like severe heart or lung diseases, liver dysfunction, cerebrovascular, cardiovascular, liver, kidney, tumor or other serious primary diseases; * patients allergic to the drug ingredients; * patients with any mental problem; * patients had participated in other drug clinical trials in the past 1 month; * patients had a history of venous or arterial thrombosis; * in certain circumstances that the researchers determined it was not suitable for the research.

Keywords: thalidomide ntdt
clinical pharmacist-led discharge education service in acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: to evaluate the impact of clinical pharmacist-led discharge education service in patients with acute coronary syndrome.

this prospective, randomized controlled study was conducted in patients with acute coronary syndrome in an cardiology service of tertiary training and research hospital. the clinical pharmacist, within the scope of the discharge education services, provided medication reconciliation, medication review, individually prepared patient medicine (pill) card, patient education (based on health belief model by using written material and video, and verbally \[by using teach back method especially for patients with low health literacy\]) and counseling (using behavior change techniques based on the capability, opportunity, and motivation behavior model). the control group received standard care.

Eligibility criteria:
inclusion criteria: * patients admitted to the cardiology department due to acute coronary syndrome * older than 18 years old exclusion criteria: * patients who transferred to another ward * patients with active malignancy * patients with alzheimer and/or dementia diagnosis * patient with \>%80 visual loss or deaf muteness reported at medical record
the role of scube-1 in ischemia-reperfusion injury

Conditions: Gonarthrosis; Diabetes

Summary: one consequence of tissue damage caused by tourniquet is ischemia-reperfusion injury. short-term ischemia leads to vasodilatation and reactive hyperemia resulting in post-ischemic reperfusion microcirculation failure and tissue edema that extends from 30 minutes to 4 hours. scube-1 is a newly defined cell surface molecule. it emerges from many developing cells, including endothelium and platelets. immunohistochemical demonstration of subendothelial matrix deposition in atherosclerosis in humans. we did not find any study that showed the post-ischemic regression of scube 1, which was shown to be significantly higher in ischemic events in the literature. in this study is aimed to investigate the location / sensitivity of scube-1 in diabetics and nondiabetics after application of regional anesthesia for ischemia-reperfusion injury induced by tourniquet application in knee prosthesis attempts in our aimed patients and compare this with other total antioxidant status (tas) and mda of ischemia-reperfusion parameters

after being taken to the operation room, the patient will be divided into two groups as group d (diabetic) and group k (control) by standardized anesthesia monitoring with 5-lead electrocardiogram (ecg), peripheral oxygen saturation (spo2) and noninvasive blood pressure measurements. in both groups, spinal anesthesia will be applied in a lateral decubitus position using a 22 gauge quincke spinal needle from the interspinal space as 0.5% heavy marcaine 10-12.5 mg 1 min. atropine 0.5 mg and ephedrine 5 mg should be administered if bradycardia develops in both groups. the disease tourniquet will be applied after induction, in accordance with the literature, to be above 150 mmhg of the systolic blood pressure.

Eligibility criteria:
inclusion criteria: * diabetes mellitus * knee replacement surgery * using a pneumatic tourniquet exclusion criteria: * coronary artery disease * renal disorders * cognitive disorders * bleeding diathesis * who have passed general anesthesia * anti-inflammatory drugs treatment * abnormal hba1c values

Keywords: scube-1
effect of relaxing music on blood pressure and resting heart rate

Conditions: Prehypertension; Blood Pressure; Resting Heart Rate

Summary: prehypertention is defined as systolic blood pressure between 120 and 139 mmhg and/or diastolic blood pressure between 80 and 89 mmhg. people with prehypertension have the higher risk to develop hypertension compared to people with normal blood pressure (normotensive) especially when getting old, therefore prehypertension is known for preliminary stage of hypertension. framingham heart study have shown the progression rate from prehypertension to hypertension was as high as 19% over 4 years. prehypertension will also lead to abnormality of the cardiovascular system. thus it is very important to identify the prehypertension at early stage, so that steps can be taken to slow down the progression to hypertension and to normalize the blood pressure level. minimal reduction in blood pressure produce a large benefit to human health, as stated in jnc (joint national committee) vii report, a 5mmhg decrease in systolic blood pressure would be able to reduce as much as 9% mortality rate caused by coronary heart disease, 14% mortality related to stroke, and 7% decrease in all-cause mortality. previous studies have focused on effect of music therapy in hypertensive elderly, prehypertensive pregnant women, prehypertensive elderly but no research has been conducted on prehypertensive young adults. in addition, prehypertension increase risk of developing cardiovascular disease, thus early intervention is needed to prevent the progression of prehypertension to hypertension status and normalize the blood pressure level.

quota sampling will be used as the sampling method. investigators would recruit 30 participants for this study.

Eligibility criteria:
inclusion criteria: * systolic blood pressure between 120 to 139 mmhg * diastolic blood pressure between 80 to 89 mmhg * not having any hearing impairment and able to listen to music using headphone * willing to participate in this study exclusion criteria: * under influence of any medication that would affect the concentration * systolic blood pressure of less than 120 or more than 140 mmhg * diastolic blood pressure of less than 80 or more than 90 mmhg
a trial investigating the relationship between pharmacodynamic and interstitial concentration for insulin detemir and human insulin

Conditions: Diabetes; Healthy

Summary: this study is conducted in europe. the aim of this study is to estimate the relationship between pharmacodynamic and interstitial pharmacokinetic steady state following intravenous (i.v.) administration of insulin detemir and human soluble insulin.


Eligibility criteria:
inclusion criteria: * healthy males between 19 and 50 years inclusive * the subject must give signed informed consent before any trial related activity. (trial related activities are any procedures that would not have been performed during the normal management of the subject) * body mass index (bmi) below 27 kg/m\^2 * fasting blood glucose maximum 6 mmol/l exclusion criteria: * participation in any other clinical trial involving other investigational products within the last 3 months